4CPS-166 Switching to alemtuzumab in patients with relapsing remitting multiple sclerosis

BACKGROUND: Alemtuzumab is a monoclonal antibody directed against the CD52 antigen on T- and B-lymphocytes indicated in adult patients with relapsing remitting multiple sclerosis (RRMS). PURPOSE: To assess safety, reason for switching, compliance with the protocol and with the criteria for use. MATE...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Arias, A, Blanc, R Menárguez, Torrón, A Martínez, Fernández, C Carriles, María, MC Rosado, Roces, L Velasco, García, I Zapico, Lozano-Blázquez, A
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 4: Clinical pharmacy services
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535247/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.257
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados